Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Four Pfizer brands to...

    Four Pfizer brands to be acquired by Piramal Enterprises for Rs 110 cr

    Written by savita thakur thakur Published On 2016-05-15T16:12:18+05:30  |  Updated On 15 May 2016 4:12 PM IST
    Four Pfizer brands to be acquired by Piramal Enterprises for Rs 110 cr

    New Delhi : Ajay Piramal-led Piramal Enterprises has entered into an agreement to acquire four brands from Pfizer for a consideration of Rs 110 crore.


    "The company's consumer products division has entered into an agreement to acquire four brands from Pfizer Ltd for a consideration of Rs 110 crore," Piramal Enterprises said in a filing to BSE.


    The acquisition includes brands Ferradol, Neko, Sloan's and Waterbury's compound, it added.


    "The agreement also includes the trademark rights for Ferradol and Waterbury's Compound in Bangladesh and Sri Lanka," Piramal Enterprises said.


    Commenting on the development, Piramal Enterprises Executive Director Nandini Piramal said: "The consumer products division of the company currently ranks seventh in India but we aim to be a top 3 player in the OTC market by 2020."


    The company believes these brands from Pfizer will fit "our portfolio and also strategically help us move closer towards our stated objective," she added.


    Piramal Enterprises Ltd (PEL) is currently present in the segments of Healthcare, Healthcare Information Management and Financial Services.


    Shares of Piramal Enterprises closed 3.89 per cent up at Rs 1,263.60 apiece on BSE.

    Ajay PiramalBSEFerradolHealthcareHealthcare Information Management and Financial ServicesNandini PiramalnekoPELPfizerPiramalPiramal enterprisesWaterbury's
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok